Confocal laser endomicroscopy in Barrett's esophagus and endoscopically inapparent Barrett's neoplasia

a prospective, randomized, double-blind, controlled, crossover trial

Kerry B. Dunbar, Patrick Okolo, Elizabeth Montgomery, Marcia Irene Canto

Research output: Contribution to journalArticle

172 Citations (Scopus)

Abstract

Background: The detection of high-grade dysplasia and cancer in Barrett's esophagus (BE) can be challenging. Confocal laser endomicroscopy (CLE) allows in vivo visualization of mucosal histology during endoscopy. Objective: To determine whether CLE with optical biopsy and targeted mucosal biopsy improves the diagnostic yield of endoscopically inapparent, BE-associated neoplasia compared to standard endoscopy with a 4-quadrant, random biopsy protocol. Design: Prospective, double-blind, randomized, crossover study. Setting: Single, tertiary-care academic center. Patients: This study involved patients with BE undergoing routine surveillance or referred for treatment of nonlocalized, endoscopically inapparent, BE-associated neoplasia. Intervention: All participants underwent both a confocal endomicroscopy with a targeted biopsy procedure and standard endoscopy with a 4-quadrant biopsy procedure in a randomized order. Main Outcome Measurements: Increase in diagnostic yield for neoplasia, reduction in mucosal biopsy number, final pathologic diagnosis. Results: CLE with targeted biopsy almost doubled the diagnostic yield for neoplasia and was equivalent to the standard protocol for the final diagnosis of neoplasia. Two thirds of patients in the surveillance group did not need any mucosal biopsies at all. Limitation: Single-center study. Conclusion: CLE with targeted biopsy significantly improves the diagnostic yield for endoscopically inapparent BE neoplasia compared to a standard endoscopy with a random-biopsy protocol. CLE with targeted biopsy also greatly reduces the number of biopsies needed per patient and allows some patients without neoplasia to completely forgo mucosal biopsy. (This trial was registered at www.clinicaltrials.gov, ID number NCT00487695.).

Original languageEnglish (US)
Pages (from-to)645-654
Number of pages10
JournalGastrointestinal Endoscopy
Volume70
Issue number4
DOIs
StatePublished - Oct 2009

Fingerprint

Barrett Esophagus
Cross-Over Studies
Lasers
Biopsy
Neoplasms
Endoscopy
Tertiary Care Centers
Histology

ASJC Scopus subject areas

  • Gastroenterology
  • Radiology Nuclear Medicine and imaging

Cite this

Confocal laser endomicroscopy in Barrett's esophagus and endoscopically inapparent Barrett's neoplasia : a prospective, randomized, double-blind, controlled, crossover trial. / Dunbar, Kerry B.; Okolo, Patrick; Montgomery, Elizabeth; Canto, Marcia Irene.

In: Gastrointestinal Endoscopy, Vol. 70, No. 4, 10.2009, p. 645-654.

Research output: Contribution to journalArticle

@article{53f03d2647f8439d86e93b701cf4f817,
title = "Confocal laser endomicroscopy in Barrett's esophagus and endoscopically inapparent Barrett's neoplasia: a prospective, randomized, double-blind, controlled, crossover trial",
abstract = "Background: The detection of high-grade dysplasia and cancer in Barrett's esophagus (BE) can be challenging. Confocal laser endomicroscopy (CLE) allows in vivo visualization of mucosal histology during endoscopy. Objective: To determine whether CLE with optical biopsy and targeted mucosal biopsy improves the diagnostic yield of endoscopically inapparent, BE-associated neoplasia compared to standard endoscopy with a 4-quadrant, random biopsy protocol. Design: Prospective, double-blind, randomized, crossover study. Setting: Single, tertiary-care academic center. Patients: This study involved patients with BE undergoing routine surveillance or referred for treatment of nonlocalized, endoscopically inapparent, BE-associated neoplasia. Intervention: All participants underwent both a confocal endomicroscopy with a targeted biopsy procedure and standard endoscopy with a 4-quadrant biopsy procedure in a randomized order. Main Outcome Measurements: Increase in diagnostic yield for neoplasia, reduction in mucosal biopsy number, final pathologic diagnosis. Results: CLE with targeted biopsy almost doubled the diagnostic yield for neoplasia and was equivalent to the standard protocol for the final diagnosis of neoplasia. Two thirds of patients in the surveillance group did not need any mucosal biopsies at all. Limitation: Single-center study. Conclusion: CLE with targeted biopsy significantly improves the diagnostic yield for endoscopically inapparent BE neoplasia compared to a standard endoscopy with a random-biopsy protocol. CLE with targeted biopsy also greatly reduces the number of biopsies needed per patient and allows some patients without neoplasia to completely forgo mucosal biopsy. (This trial was registered at www.clinicaltrials.gov, ID number NCT00487695.).",
author = "Dunbar, {Kerry B.} and Patrick Okolo and Elizabeth Montgomery and Canto, {Marcia Irene}",
year = "2009",
month = "10",
doi = "10.1016/j.gie.2009.02.009",
language = "English (US)",
volume = "70",
pages = "645--654",
journal = "Gastrointestinal Endoscopy",
issn = "0016-5107",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Confocal laser endomicroscopy in Barrett's esophagus and endoscopically inapparent Barrett's neoplasia

T2 - a prospective, randomized, double-blind, controlled, crossover trial

AU - Dunbar, Kerry B.

AU - Okolo, Patrick

AU - Montgomery, Elizabeth

AU - Canto, Marcia Irene

PY - 2009/10

Y1 - 2009/10

N2 - Background: The detection of high-grade dysplasia and cancer in Barrett's esophagus (BE) can be challenging. Confocal laser endomicroscopy (CLE) allows in vivo visualization of mucosal histology during endoscopy. Objective: To determine whether CLE with optical biopsy and targeted mucosal biopsy improves the diagnostic yield of endoscopically inapparent, BE-associated neoplasia compared to standard endoscopy with a 4-quadrant, random biopsy protocol. Design: Prospective, double-blind, randomized, crossover study. Setting: Single, tertiary-care academic center. Patients: This study involved patients with BE undergoing routine surveillance or referred for treatment of nonlocalized, endoscopically inapparent, BE-associated neoplasia. Intervention: All participants underwent both a confocal endomicroscopy with a targeted biopsy procedure and standard endoscopy with a 4-quadrant biopsy procedure in a randomized order. Main Outcome Measurements: Increase in diagnostic yield for neoplasia, reduction in mucosal biopsy number, final pathologic diagnosis. Results: CLE with targeted biopsy almost doubled the diagnostic yield for neoplasia and was equivalent to the standard protocol for the final diagnosis of neoplasia. Two thirds of patients in the surveillance group did not need any mucosal biopsies at all. Limitation: Single-center study. Conclusion: CLE with targeted biopsy significantly improves the diagnostic yield for endoscopically inapparent BE neoplasia compared to a standard endoscopy with a random-biopsy protocol. CLE with targeted biopsy also greatly reduces the number of biopsies needed per patient and allows some patients without neoplasia to completely forgo mucosal biopsy. (This trial was registered at www.clinicaltrials.gov, ID number NCT00487695.).

AB - Background: The detection of high-grade dysplasia and cancer in Barrett's esophagus (BE) can be challenging. Confocal laser endomicroscopy (CLE) allows in vivo visualization of mucosal histology during endoscopy. Objective: To determine whether CLE with optical biopsy and targeted mucosal biopsy improves the diagnostic yield of endoscopically inapparent, BE-associated neoplasia compared to standard endoscopy with a 4-quadrant, random biopsy protocol. Design: Prospective, double-blind, randomized, crossover study. Setting: Single, tertiary-care academic center. Patients: This study involved patients with BE undergoing routine surveillance or referred for treatment of nonlocalized, endoscopically inapparent, BE-associated neoplasia. Intervention: All participants underwent both a confocal endomicroscopy with a targeted biopsy procedure and standard endoscopy with a 4-quadrant biopsy procedure in a randomized order. Main Outcome Measurements: Increase in diagnostic yield for neoplasia, reduction in mucosal biopsy number, final pathologic diagnosis. Results: CLE with targeted biopsy almost doubled the diagnostic yield for neoplasia and was equivalent to the standard protocol for the final diagnosis of neoplasia. Two thirds of patients in the surveillance group did not need any mucosal biopsies at all. Limitation: Single-center study. Conclusion: CLE with targeted biopsy significantly improves the diagnostic yield for endoscopically inapparent BE neoplasia compared to a standard endoscopy with a random-biopsy protocol. CLE with targeted biopsy also greatly reduces the number of biopsies needed per patient and allows some patients without neoplasia to completely forgo mucosal biopsy. (This trial was registered at www.clinicaltrials.gov, ID number NCT00487695.).

UR - http://www.scopus.com/inward/record.url?scp=70349311118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349311118&partnerID=8YFLogxK

U2 - 10.1016/j.gie.2009.02.009

DO - 10.1016/j.gie.2009.02.009

M3 - Article

VL - 70

SP - 645

EP - 654

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

IS - 4

ER -